Handle region peptide counteracts the beneficial effects of the renin inhibitor aliskiren in spontaneously hypertensive rats

Hypertension

Volumn 57, Issue 4, 2011, Pages 852-858

  Van Esch, Joep H M ^a   Van Veghel, Richard ^a   Garrelds, Ingrid M ^a   Leijten, Frank ^a   Bouhuizen, Angelique M ^a   Danser, A H Jan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

(pro)renin; aliskiren; angiotensin; handle region peptide; spontaneously hypertensive rat

Indexed keywords

ALISKIREN; ANGIOTENSIN 1 RECEPTOR; ANTIHYPERTENSIVE AGENT; BRADYKININ; HANDLE REGION PEPTIDE; RENIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY HEMODYNAMICS; DRUG EFFECT; HEART RATE; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

AMIDES; ANALYSIS OF VARIANCE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRADYKININ; DRUG INTERACTIONS; ENDOTHELIUM, VASCULAR; FUMARATES; HEART RATE; HYPERTENSION; INFUSION PUMPS, IMPLANTABLE; MALE; OLIGOPEPTIDES; RATS; RATS, INBRED SHR; RENIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TELEMETRY;

EID: 79953196418     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.169060     Document Type: Article

References (39)

1. van Esch JHM, Moltzer E, van Veghel R, Garrelds IM, Leijten F, Bouhuizen AM, Danser AHJ. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. J Hypertens. 2010; 28:2145-2155.
2. Westermann D, Riad A, Lettau O, Roks A, Savvatis K, Becher PM, Escher F, Danser AHJ, Schultheiss HP, Tschöpe C. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension. 2008;52:1068-1075.
3. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlof B. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119:530-537.
4. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Müller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Danser AHJ, Nguyen G. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension. 2008;52:130-136.
5. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJA, Burcklé CA, Müller DN, Bader M, Nguyen G, Danser AHJ. Prorenin is the endogenous agonist of the (pro)renin receptor: binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens. 2007;25:2441-2453. (Pubitemid 350060383)
6. Batenburg WW, de Bruin RJA, van Gool JMG, Müller DN, Bader M, Nguyen G, Danser AHJ. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2008;28:1151-1157.
7. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AH, Ishida Y, Inagami T, Saruta T. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest. 2004;114:1128-1135. (Pubitemid 39578702)
8. Krebs C, Weber M, Steinmetz O, Meyer-Schwesinger C, Stahl R, Danser AHJ, Garrelds IM, van Goor H, Nguyen G, Müller DN, Wenzel U. Effect of (pro)renin receptor inhibition by a decoy peptide on renal damage in the clipped kidney of Goldblatt rats. Kidney Int. 2008;74:823-824.
9. Feldt S, Maschke U, Dechend R, Luft FC, Müller DN. The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling. J Am Soc Nephrol. 2008;19:743-748.
10. Campbell DJ. Critical review of prorenin and (pro)renin receptor research. Hypertension. 2008;51:1259-1264. (Pubitemid 351555933)
11. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Suzuki F, Nakagawa T, Nishiyama A, Inagami T, Hayashi M. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension. 2006;47:894-900. (Pubitemid 44297561)
12. van Esch JHM, Oosterveer CR, Batenburg WW, van Veghel R, Danser AHJ. Effects of angiotensin II and its metabolites in the rat coronary vascular bed: Is angiotensin III the preferred ligand of the angiotensin AT(2) receptor? Eur J Pharmacol. 2008;588:286-293.
13. van Kerckhoven R, Saxena PR, Schoemaker RG. Restored capillary density in spared myocardium of infarcted rats improves ischemic tolerance. J Cardiovasc Pharmacol. 2002;40:370-380. (Pubitemid 34971354)
14. de Lannoy LM, Danser AHJ, van Kats JP, Schoemaker RG, Saxena PR, Schalekamp MADH. Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart: local production of angiotensin I. Hypertension. 1997;29:1240-1251. (Pubitemid 27233172)
15. Danser AHJ, van Kats JP, Admiraal PJJ, Derkx FHM, Lamers JMJ, Verdouw PD, Saxena PR, Schalekamp MADH. Cardiac renin and angiotensins: uptake from plasma versus in situ synthesis. Hypertension. 1994; 24:37-48. (Pubitemid 24195402)
16. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 2007;8:R19.
17. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens. 2005;23:417-426. (Pubitemid 40279646)
18. Webb RL, Navarrete AE, Davis S, de Gasparo M. Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats. J Hypertens. 1998;16:843-852. (Pubitemid 28247968)
19. Nabi AH, Kageshima A, Uddin MN, Nakagawa T, Park EY, Suzuki F. Binding properties of rat prorenin and renin to the recombinant rat renin/prorenin receptor prepared by a baculovirus expression system. Int J Mol Med. 2006;18:483-488.
20. Danser AHJ, van Kesteren CAM, Bax WA, Tavenier M, Derkx FHM, Saxena PR, Schalekamp MADH. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts: evidence for renin binding. Circulation. 1997;96:220-226. (Pubitemid 27298424)
21. Klotz S, Burkhoff D, Garrelds IM, Boomsma F, Danser AHJ. The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences? Eur Heart J. 2009;30:805-812.
22. Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, Nabi AH, Nishiyama A, Sugaya T, Hayashi M, Inagami T. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol. 2006; 17:1950-1961. (Pubitemid 44036179)
23. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, Ruger H, Goschke R, Stutz S, Fuhrer W, Schilling W, Rigollier P, Yamaguchi Y, Cumin F, Baum HP, Schnell CR, Herold P, Mah R, Jensen C, O'Brien E, Stanton A, Bedigian MP. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003;308:698-705. (Pubitemid 36976519)
24. Krop M, Garrelds IM, de Bruin RJA, van Gool JMG, Fisher ND, Hollenberg NK, Danser AHJ. Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension. 2008;52:1076-1083.
25. Cumin F, Evin G, Fehrentz JA, Seyer R, Castro B, Ménard J, Corvol P. Inhibition of human renin by synthetic peptides derived from its prosegment. J Biol Chem. 1985;260:9154-9157. (Pubitemid 15249892)
26. Wilkinson-Berka JL, Heine R, Tan G, Cooper ME, Hatzopoulos KM, Fletcher EL, Binger KJ, Campbell DJ, Miller AG. RILLKKMPSV influences the vasculature, neurons and glia, and (pro)renin receptor expression in the retina. Hypertension. 2010;55:1454-1460.
27. Lastra G, Habibi J, Whaley-Connell AT, Manrique C, Hayden MR, Rehmer J, Patel K, Ferrario C, Sowers JR. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology. 2009;150:2561-2568.
28. Whaley-Connell A, Nistala R, Habibi J, Hayden MR, Schneider RI, Johnson MS, Tilmon R, Rehmer N, Ferrario CM, Sowers JR. Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol. 2009;298:F655-F661.
29. Moltzer E, Verkuil AV, van Veghel R, Danser AHJ, van Esch JHM. Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptormediated vasodilation. Hypertension. 2010;55:516-522.
30. Fisher NDL, Danser AHJ, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation. 2008;117:3199-3205.
31. Mercure C, Prescott G, Lacombe MJ, Silversides DW, Reudelhuber TL. Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies. Hypertension. 2009;53:1062-1069.
32. Campbell DJ, Karam H, Ménard J, Bruneval P, Mullins JJ. Prorenin contributes to angiotensin peptide formation in transgenic rats with rat prorenin expression targeted to the liver. Hypertension. 2009;54: 1248-1253.
33. Peters B, Grisk O, Becher B, Wanka H, Kuttler B, Ludemann J, Lorenz G, Rettig R, Mullins JJ, Peters J. Dose-dependent titration of prorenin and blood pressure in Cyp1a1ren-2 transgenic rats: absence of prorenininduced glomerulosclerosis. J Hypertens. 2008;26:102-109. (Pubitemid 350301935)
34. Burcklé CA, Danser AHJ, Müller DN, Garrelds IM, Gasc JM, Popova E, Plehm R, Peters J, Bader M, Nguyen G. Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension. 2006;47: 552-556. (Pubitemid 43843874)
35. Kaneshiro Y, Ichihara A, Sakoda M, Takemitsu T, Nabi AH, Uddin MN, Nakagawa T, Nishiyama A, Suzuki F, Inagami T, Itoh H. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc Nephrol. 2007;18: 1789-1795. (Pubitemid 46870315)
36. Kinouchi K, Ichihara A, Sano M, Sun-Wada GH, Wada Y, Kurauchi-Mito A, Bokuda K, Narita T, Oshima Y, Sakoda M, Tamai Y, Sato H, Fukuda K, Itoh H. The (pro)renin receptor/ATP6AP2 is essential for vacuolar H-ATPase assembly in murine cardiomyocytes. Circ Res. 2010;107:30-34.
37. Satofuka S, Ichihara A, Nagai N, Noda K, Ozawa Y, Fukamizu A, Tsubota K, Itoh H, Oike Y, Ishida S. (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes. 2009;58: 1625-1633.
38. Leckie BJ, Bottrill AR. A specific binding site for the prorenin propart peptide Arg10-Arg20 does not occur on human endothelial cells. J Renin Angiotensin Aldosterone Syst. In press.
39. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H, Dechend R, Fiebeler A, Burcklé CA, Contrepas A, Danser AHJ, Bader M, M̈uller DN. Prorenin and renin-induced ERK 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension. 2008;51:682-688. (Pubitemid 351301521)